Organon inks $103M deal for pertuzumab and denosumab biosimilars

Organon is looking to boost its biosimilar portfolio with two well-known brand copies in development by Shanghai-based Henlius Biotech.

The women’s health pharma is paying $73 million upfront, plus up to $30 million in 2022 milestone payments, for the pertuzumab biosimilar to Roche’s Genentech’s breast cancer drug Perjeta and the...

Click to view original post